Moderna narrows bird flu vaccine research in U.S. amid shifting public health priorities
Original framing: “Moderna continues bird flu vax study, but limits work in the U.S.” — STAT News
Scientific evidence supports the need for broad, open-access vaccine research to address zoonotic threats. However, Moderna’s limited U.S. bird flu work suggests a shift toward niche markets rather than public health preparedness, which undermines global pandemic resilience.
The decision by Moderna to limit U.S. bird flu vaccine research reflects a systemic trend in which corporate interests shape public health priorities, often at the expense of global equity and preparedness.
This framing obscures the historical pattern of vaccine nationalism and the marginalization of indigenous and traditional knowledge systems that have long contributed to disease prevention. By integrating cross-cultural approaches, public funding, and inclusive governance, we can build a more resilient and equitable global health infrastructure. The future of pandemic preparedness depends on dismantling the profit-driven model and embracing collaborative, community-centered solutions.